www.uhasselt.be
DSpace

Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/18984

Title: Whole Cell Therapeutic Vaccine Modified With Hyper-IL6 for Combinational Treatment of Nonresected Advanced Melanoma
Authors: Jacek, Mackiewicz
Aldona, Karczewska-Dzionk
Maria, Laciak
Malgorzata, Kapcinska
Maciej, Wiznerowicz
BURZYKOWSKI, Tomasz
Zakowska, Monika
Stefan, Rose-John
Andrzej, Mackiewicz
Issue Date: 2015
Publisher: LIPPINCOTT WILLIAMS & WILKINS
Citation: MEDICINE, 94 (21)
Abstract: Active specific immunotherapy of cancer requires an efficient induction and effector phase. The induction covers potent activation of anti-tumor response, whereas effector breaks the immunosuppression. We report efficacy of therapeutic melanoma vaccine (AGI-101H) used alone in advanced disease as a candidate for further combined treatment. In adjuvant setting in patients with resected metastases AGI-101 Hcombined with surgery of recurring disease demonstrated long-term survival. Seventy-seven patients with nonresectable melanoma (8% IIIB, 21% IIIC, 71% IV) were enrolled. AGI-101H was administered 8 x every 2 weeks, and then every month. At progression, maintenance was continued or induction was repeated and followed by maintenance. Median follow-up was 139.3 months. The median overall survival (OS) was 17.3 months; in patients with WHO 0-1 was 20.3 months. Complete response (CR) and partial response (PR) were observed in 19.4% and 9% of pts. Disease control rate was 54.5% of pts. The median CR+PR duration was 32 months. Reinduction was performed in 36.3% patients following disease progression with 46.6% of CR+PR. No grade 3/4 adverse events were observed. Treatment with AGI-101H of melanoma patients is safe and effective. AGI-101H is a good candidate for combinatorial treatment with immune check-points inhibitors or tumor hypoxia normalizators.
Notes: [Jacek, Mackiewicz; Maria, Laciak; Malgorzata, Kapcinska; Maciej, Wiznerowicz; Zakowska, Monika; Andrzej, Mackiewicz] Univ Med Sci, Chair Med Biotechnol, PL-61866 Poznan, Poland. [Jacek, Mackiewicz; Aldona, Karczewska-Dzionk; Maciej, Wiznerowicz; Andrzej, Mackiewicz] Greater Poland Canc Ctr, Dept Diagnost & Canc Immunol, Poznan, Poland. [Jacek, Mackiewicz] Poznan Univ Med Sci, Clin Hosp, Dept Med & Expt Oncol, Poznan, Poland. [Tomasz, Burzykowski] Hasselt Univ, Interuniv Inst Biostat & Stat Bioinformat, Diepenbeek, Belgium. [Stefan, Rose-John] Univ Kiel, Inst Biochem, Kiel, Germany. [Maria, Laciak; Malgorzata, Kapcinska; Andrzej, Mackiewicz] BioContract Sp Zoo, Poznan, Poland.Correspondence: Jacek Mackiewicz, Chair of Medical Biotechnology, University of Medical Sciences, 15, Garbary St., 61-866 Poznan, Poland (e-mail: jmackiewicz@ump.edu.pl).
URI: http://hdl.handle.net/1942/18984
DOI: 10.1097/MD.0000000000000853
ISI #: 000355284100016
ISSN: 0025-7974
Category: A1
Type: Journal Contribution
Validation: ecoom, 2016
Appears in Collections: Research publications

Files in This Item:

Description SizeFormat
article200.25 kBAdobe PDF

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.